Rani Therapeutics Holdings, INC Schedule 13G passive stakes

Vanguard Capital Management has reported a beneficial ownership of 4.49% in Rani Therapeutics Holdings Inc. as of June 30, 2026.

SymBiosis Capital Partners, LLC has reported beneficial ownership of 4.4% of Rani Therapeutics Holdings, Inc. Class A Common Stock as of March 27, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.12% of Rani Therapeutics Holdings Inc. common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Rani Therapeutics Holdings Inc. following an internal realignment.

AWM Investment Company, Inc. has disclosed a significant 9.9% beneficial ownership stake in Rani Therapeutics Holdings, Inc. through various funds.

SymBiosis Capital Partners, LLC has reported a 6.5% beneficial ownership stake in Rani Therapeutics Holdings, Inc.'s Class A Common Stock.

The Vanguard Group has reported a 5.23% beneficial ownership stake in Rani Therapeutics Holdings Inc. common stock as of December 31, 2025.

Armistice Capital and Steven Boyd have reported a beneficial ownership of 4.99% in Rani Therapeutics Holdings, Inc., indicating a reduction in their stake below the 5% threshold.

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Rani Therapeutics Holdings, Inc., primarily through shares and warrants.

A group of investment entities led by Raymond Debbane has disclosed a 9.99% passive ownership stake in Rani Therapeutics Holdings, Inc. Class A Common Stock.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.79% in Rani Therapeutics Holdings-A, totaling 4,312,354 shares of common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a 4.3% beneficial ownership stake in Rani Therapeutics Holdings, Inc.'s Class A Common Stock.

Orca Capital AG has reported a significant 9.9% beneficial ownership stake in Rani Therapeutics Holdings, Inc., holding 4,354,000 shares of Class A Common Stock.